• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors.

作者信息

Cooper Shaun D, Cowdrey Molly C E, Linos Konstantinos D, Lefferts Joel A, Basic Katherina K

机构信息

Dr. Cooper is from the Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. Drs. Cowdrey, Linos, and Lefferts are from the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Dr. Cowdrey is from the Section of Dermatology, and Drs. Linos and Lefferts are from the Department of Pathology and Laboratory Medicine, Dermatopathology Division. Dr. Basic is from the James A. Haley Veterans Hospital, Tampa, and the Department of Dermatology, Morsani College of Medicine, University of South Florida, Tampa.

出版信息

Cutis. 2021 Apr;107(4):E5-E7. doi: 10.12788/cutis.0233.

DOI:10.12788/cutis.0233
PMID:34096852
Abstract
摘要

相似文献

1
Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors.
Cutis. 2021 Apr;107(4):E5-E7. doi: 10.12788/cutis.0233.
2
Anti-TNFα-induced psoriasis under treatment of hidradenitis suppurativa: report of 2 cases.
G Ital Dermatol Venereol. 2020 Jun;155(3):377-379. doi: 10.23736/S0392-0488.18.06054-6. Epub 2018 Jul 17.
3
Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.目前用于治疗化脓性汗腺炎的生物疗法的代谢、药代动力学和毒理学问题。
Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1019-1037. doi: 10.1080/17425255.2020.1810233. Epub 2020 Oct 12.
4
Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.接受 TNF-α 抑制剂治疗的患者中出现矛盾性化脓性汗腺炎：病例系列、系统评价和病例荟萃分析。
Dermatology. 2020;236(4):307-313. doi: 10.1159/000506074. Epub 2020 Mar 5.
5
Squamous cell carcinoma of the cervix arising in a patient on adalimumab � a need for cervical screenings in patients on tumor necrosis factor inhibitors.一名使用阿达木单抗的患者发生宫颈鳞状细胞癌——肿瘤坏死因子抑制剂使用者需进行宫颈筛查
Dermatol Online J. 2018 May 15;24(5):13030/qt3fs049h2.
6
Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review.
Br J Dermatol. 2021 Mar;184(3):555-557. doi: 10.1111/bjd.19591. Epub 2021 Feb 8.
7
Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.戈利木单抗用于治疗既往肿瘤坏死因子-α治疗失败的化脓性汗腺炎患者。
J Invest Dermatol. 2021 Dec;141(12):2975-2979. doi: 10.1016/j.jid.2021.04.026. Epub 2021 Jun 5.
8
Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases.18岁以下化脓性汗腺炎患者使用肿瘤坏死因子抑制剂的治疗：12例病例系列
J Am Acad Dermatol. 2020 Jul;83(1):199-201. doi: 10.1016/j.jaad.2020.02.071. Epub 2020 Mar 6.
9
Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study.接受抗TNF-α治疗的化脓性汗腺炎患者发生鳞状细胞癌的风险——一项为期12年的多中心前瞻性观察研究结果
J Eur Acad Dermatol Venereol. 2024 Sep;38(9):e807-e809. doi: 10.1111/jdv.19916. Epub 2024 Feb 26.
10
Kyrle disease associated with hidradenitis suppurativa successfully treated with tumour necrosis factor inhibition.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e395-e397. doi: 10.1111/jdv.16296. Epub 2020 Mar 4.

引用本文的文献

1
Hidradenitis suppurativa and squamous cell carcinoma: a systematic review of the literature.化脓性汗腺炎与鳞状细胞癌：文献系统综述
Postepy Dermatol Alergol. 2023 Jun;40(3):350-354. doi: 10.5114/ada.2023.126563. Epub 2023 Apr 21.
2
A complication in a patient with hidradenitis suppurativa taking adalimumab.一位服用阿达木单抗的化脓性汗腺炎患者出现的并发症。
JAAD Case Rep. 2022 Jul 5;27:147-150. doi: 10.1016/j.jdcr.2022.05.045. eCollection 2022 Sep.